Lifecare Q2 2024: High activity – initial positive signs from longevity trials - Redeye

Redeye updates its view on Lifecare following the Q2 report and recent company developments, including confirmed sensor longevity of nine weeks in dogs, a strategic cooperation, and a new patent filing, among other things.

Länk till analysen i sin helhet: https://www.redeye.se/research/1034762/lifecare-q2-2024-initial-positive-signs-from-longevity-trials?utm_source=finwire&utm_medium=RSS